Scandinavian Biopharma: €3.0m

Case

Scandinavian Biopharma is a Swedish research-based biotech company specialist in marketing and sales of vaccines, immunoglobulin’s, biodefense, antidotes and diagnostic tests. Scandinavian Biopharma received € 3.0M from the SME Instrument HORIZON 2020, phase 2.

“The contribution from the EU Commission is a strong recognition of our research, which strives toward developing a globally unique ETEC vaccine. The EU grant will be used to accelerate the clinical development of the vaccine and to take a significant step towards commercialisation. GAEU Consulting has been responsible for our application. We are very satisfied with the quality of the work effort and commitment from the team in Kraków.”

- Björn Sjöstrand, CEO, Scandinavian Biopharma